Loading organizations...
Loading organizations...
Developer of cancer immune therapies for hematological malignancies.
Gracell Biotechnologies has raised $185.0M across 2 funding rounds.
Gracell Biotechnologies has raised $185.0M in total across 2 funding rounds.
Gracell Biotechnologies has raised $185.0M in total across 2 funding rounds.
Gracell Biotechnologies's investors include Morningside Ventures, OrbiMed, Wellington Management, King Star Med, Lilly Asia Ventures, Temasek Holdings, Vivo Capital, Temasek, Chengdu Miaoji, King Star Capital, Kington Capital.
Gracell Biotechnologies has raised $185.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 29, 2020 | $100.0M Series C | Morningside Ventures, OrbiMed, Wellington Management | King Star Med, Lilly Asia Ventures, Temasek Holdings, Vivo Capital |
| Feb 25, 2019 | $85.0M Series B | Temasek | Chengdu Miaoji, King Star Capital, Kington Capital, Lilly Asia Ventures |